Information
- ID of tender
-
72595
- Name of content of tender
-
Lieky ATC skupiny L01FA01
- Tender ref. no.
-
17/2025/JH
- Public tender journal ref. no.
-
18404-MST
- EU journal ref. no.
-
https://ted.europa.eu/sk/notice/-/detail/767138-2025
- Type of tender
-
Nadlimitná zákazka
- Type of public tender
-
Verejná súťaž podľa § 66 (7)
- Type of procurement
-
Goods
- Estimated value
-
6 015 810,00 EUR
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Tender split into parts
- Yes
- Centralised tender
-
No
- NUTS
-
SK0101 - Okres Bratislava I
- Brief description of tender or procurement
-
Lieky ATC skupiny L01FA01
- For evaluation the price is determined
-
not including VAT
Schedule
-
Lehota na predkladanie ponúk
-
19.12.2025 10:00:00
-
Planned opening of bids
-
19.12.2025 10:05:00
Documents
|
Name of document
|
Type
|
Size
|
Uploaded on
|
|
|
Rámcová dohoda časť 3
|
Súťažné podklady
|
650.72 KB
|
18.11.2025 08:54:15
|
|
|
Rámcová dohoda časť 2
|
Súťažné podklady
|
650.69 KB
|
18.11.2025 08:53:58
|
|
|
Rámcová dohoda časť 1
|
Súťažné podklady
|
650.81 KB
|
18.11.2025 08:53:43
|
|
|
Súťažné podklady
|
Súťažné podklady
|
641.03 KB
|
18.11.2025 08:53:18
|
|
Lieky ATC skupiny L01FA01 časť 1
- Status
-
Ongoing
- Predicted value not including VAT
-
1 797 000,00 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Lieky ATC skupiny L01FA01 časť 2
- Status
-
Ongoing
- Predicted value not including VAT
-
3 306 485,00 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- One-off Contract
Lieky ATC skupiny L01FA01 časť 3
- Status
-
Ongoing
- Predicted value not including VAT
-
912 325,00 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement